This critically-important study works with our belief that the future of cancer treatment is based on an in-depth knowledge of the genetic make-up of individual patients’ cancer at the molecular level, through the use of molecular lab tests like Caris Target Today, Dr. Daniel Von Hoff, physician-in-chief at The Translational Genomics Study Institute, Chief Scientific Officer at US Scottsdale and Oncology Healthcare, and a consultant to Caris Existence Sciences, commented upon the scholarly study.ITP has historically been considered an illness of platelet destruction although recent data suggest that your body’s natural platelet production processes in ITP are unable to compensate for low degrees of platelets in the blood. Increasing the rate of platelet production may address low platelet amounts associated with ITP. Currently, there are 90 around,000 adult chronic ITP patients in Europe and the United States . ITP affects about doubly many adult females as men.